Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

ClinicalTrials.gov ID: NCT05393089

Public ClinicalTrials.gov record NCT05393089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Subjects With Pseudophakic Presbyopia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Presbyopia is a condition in which the eye exhibits a diminished ability to focus on near objects with increasing age. This study will assess the safety and exploratory efficacy of AGN-190584 is in treating participants with pseudophakic presbyopia. AGN-190584 is approved (in the United States) for use in adults with presbyopia (including those who are pseudophakic) and this study is being conducted to better understand the safety and efficacy in the pseudophakic presbyopia population. This study is double-masked meaning that neither the participants nor the study doctors will know who will be given AGN-190584 and who will be given vehicle (does not contain treatment drug). Study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to vehicle. Approximately 150 participants aged 40-80 years with pseudophakic presbyopia will be enrolled in approximately 30 sites in the US. Participants will receive eye drops of AGN-190584 or vehicle once daily in the morning in each eye for 14 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study. The effect of the treatment will be evaluated by medical assessments, checking for side effects and completing questionnaires.

Study identification

NCT ID
NCT05393089
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
Allergan
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2022
Primary completion
Apr 3, 2023
Completion
Apr 3, 2023
Last update posted
Jun 28, 2022

2022 – 2023

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
30
Facility City State ZIP Site status
Trinity Research Group /ID# 243541 Dothan Alabama 36301
Arizona Eye Center /ID# 243897 Chandler Arizona 85224
Global Research Management /ID# 243544 Glendale California 91204-2500
United Medical Research Institute /ID# 243531 Inglewood California 90301
Salvay Vision /ID# 243828 Newport Beach California 92663-3600
The Eye Research Foundation /ID# 243524 Newport Beach California 92663-3637
Sacramento Eye Consultants /ID# 243538 Sacramento California 95815
Nature Coast Clinical Research - Crystal River /ID# 243519 Crystal River Florida 34429
Segal Drug Trials, Inc /ID# 243521 Delray Beach Florida 33484
Eye Associates of Fort Meyers /ID# 243545 Fort Myers Florida 33901
Levenson Eye Associates Inc. /ID# 243532 Jacksonville Florida 32204
Emory University /ID# 243534 Atlanta Georgia 30322-1013
Clayton Eye Clinical Research, LLC /ID# 243530 Morrow Georgia 30260-4180
Coastal Research Associates /ID# 243525 Roswell Georgia 30076
Kannarr Eye Care /ID# 243542 Pittsburg Kansas 66762-2620
Cincinnati Eye Institute- Edgewood /ID# 243810 Edgewood Kentucky 41017-3415
The Eye Care Institute /ID# 243588 Louisville Kentucky 40206-1738
Fraser Eye Center /ID# 244038 Fraser Michigan 48026
Silverstein Eye Centers /ID# 243546 Kansas City Missouri 64034
Eye Associates of North Jersey /ID# 243913 Dover New Jersey 07801-1629
Northern New Jersey Eye Institute PA /ID# 243522 South Orange New Jersey 07079-1855
Rochester Ophthalmological Group PC /ID# 243539 Rochester New York 14618-2616
EyeCare Professionals Inc /ID# 243938 Powell Ohio 43065
Scott and Christie and Associates /ID# 243548 Cranberry Township Pennsylvania 16066
University Eye Surgeons /ID# 243926 Maryville Tennessee 37805
Advancing Vision Research /ID# 243529 Smyrna Tennessee 37167
Key-Whitman Eye Center /ID# 243928 Dallas Texas 75243
Eye associates /ID# 243526 San Antonio Texas 78229
Parkhurst Nuvision /ID# 244041 San Antonio Texas 78229
Hoopes, Durrie, Rivera Research /ID# 243535 Draper Utah 84020-7133
Country Hills Eye Center /ID# 243520 Ogden Utah 84403-2200
Southern Utah Medical Research /ID# 243931 St. George Utah 84790

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05393089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 28, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05393089 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →